Is VSTM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on VS-7375 in KRAS G12D pancreatic cancer, with revenue (ttm) at ~$87.5M (incl. $15M COPIKTRA milestone). The bear case rests on the clearest risk is that VS-7375's early results do not hold up. Analysts covering it are spread from $12.00 to $24.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The clearest risk is that VS-7375's early results do not hold up. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $12.00, +38.7% from the $8.65 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

VS-7375 in KRAS G12D pancreatic cancer. KRAS G12D is the most common driver mutation in pancreatic ductal adenocarcinoma, a cancer where second-line chemotherapy has historically produced low response rates. The most optimistic analyst target on VSTM is $24.00, +177.5% from the $8.65 price. That figure is only reachable if this thesis works close to its best case.

The clearest risk is that VS-7375's early results do not hold up. The pancreatic response rate comes from 22 patients in a single-arm study with about six months of median follow-up, and response rates often fall, and durability often disappoints, as trials grow and move into randomized Phase 3 designs. Competition is a second risk: Revolution Medicines is running Phase 3 trials of RAS inhibitors in pancreatic cancer, and Eli Lilly, AstraZeneca, Boehringer Ingelheim and several Chinese biotechs have G12D or pan-RAS programs, many backed by far larger budgets. Third, Verastem lost ~$34.7 million in Q2 2026 and ~$200 million over the trailing twelve months, and three Phase 3 programs would be expensive, so further equity raises are plausible. Fourth, its ovarian product holds accelerated approval, which depends on the RAMP 301 confirmatory trial due in mid-2027. The Oberland royalty deal also gives up a share of future product revenue. Finally, VS-7375 is in-licensed from GenFleet, so milestones and royalties owed to the licensor reduce the economics, and the stock has swung between ~$3.43 and ~$10.82 over the past year. The most pessimistic published target is $12.00, +38.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Verastem Oncology is a Needham, Massachusetts biotech focused on the RAS/MAPK pathway, the signaling chain that is mutated in roughly a third of human cancers.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (VS-7375 in KRAS G12D pancreatic cancer) stalling in the reported numbers rather than in the narrative, the risk above (the clearest risk is that VS-7375's early results do not hold up) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Verastem Oncology develops and sells cancer drugs that target the RAS/MAPK pathway, a growth-signaling chain that is mutated in many tumors. Its approved product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib and treats adults with recurrent KRAS-mutated low-grade serous ovarian cancer after prior systemic therapy. It received FDA accelerated approval in May 2025 and generated ~$25.1 million of sales in the second quarter of 2026. The company's lead pipeline asset is VS-7375, an oral KRAS G12D inhibitor licensed from GenFleet Therapeutics and being tested in pancreatic, lung and colorectal cancer. Verastem is based in Needham, Massachusetts. It also earns occasional milestones from COPIKTRA, a drug it sold to Secura Bio, and it funds itself through a mix of product sales, royalty financing and stock offerings.

On October 14, 2026, Verastem reported updated results from its TARGET-D 101 trial of VS-7375. Among 22 previously treated pancreatic cancer patients on the 900 mg dose, 41% had confirmed responses, rising to 50% among the eight treated in second line, with 10% of patients having grade 3 or worse treatment-related side effects. It also showed a 43% confirmed response rate in previously treated lung cancer and said it had FDA alignment on a first-line pancreatic Phase 3 planned to open by the end of 2026. The same day it priced a ~$250 million offering at $8.00 per share and announced that Michael Bailey will succeed Dan Paterson as CEO on January 1, 2027. The shares jumped in early trading, and several analysts raised price targets, though the stock gave back some gains later in the week.

Verastem has growing revenue but is not profitable. In the second quarter of 2026 it reported ~$40.1 million of total revenue, made up of ~$25.1 million of AVMAPKI FAKZYNJA CO-PACK sales and a one-time $15 million COPIKTRA milestone. Against that it spent ~$41.3 million on research and development and ~$27.4 million on selling, general and administrative costs, leaving a GAAP net loss of ~$34.7 million, or $0.35 per share. Over the trailing twelve months the net loss was roughly $200 million. Spending is likely to rise rather than fall as VS-7375 moves into registration-directed Phase 2 and Phase 3 trials, so profitability depends on a much larger commercial business than the company has today, most plausibly through VS-7375 approval in one or more indications.